ATE398619T1 - Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine - Google Patents

Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine

Info

Publication number
ATE398619T1
ATE398619T1 AT05792946T AT05792946T ATE398619T1 AT E398619 T1 ATE398619 T1 AT E398619T1 AT 05792946 T AT05792946 T AT 05792946T AT 05792946 T AT05792946 T AT 05792946T AT E398619 T1 ATE398619 T1 AT E398619T1
Authority
AT
Austria
Prior art keywords
cdk2
colon
breast
lung
treatment
Prior art date
Application number
AT05792946T
Other languages
English (en)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Giacomo Pizzolato
Yi Ren
Kshitij Chhabilbhai Thakkar
Peter Wovkulich
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE398619(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE398619T1 publication Critical patent/ATE398619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05792946T 2004-10-13 2005-10-04 Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine ATE398619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61817404P 2004-10-13 2004-10-13

Publications (1)

Publication Number Publication Date
ATE398619T1 true ATE398619T1 (de) 2008-07-15

Family

ID=35311946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05792946T ATE398619T1 (de) 2004-10-13 2005-10-04 Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine

Country Status (25)

Country Link
US (1) US7524840B2 (de)
EP (1) EP1802625B1 (de)
JP (1) JP2008515939A (de)
KR (1) KR100858262B1 (de)
CN (2) CN101039946B (de)
AR (1) AR051326A1 (de)
AT (1) ATE398619T1 (de)
AU (1) AU2005293818A1 (de)
BR (1) BRPI0518152A (de)
CA (1) CA2582985A1 (de)
DE (1) DE602005007623D1 (de)
DK (1) DK1802625T3 (de)
ES (1) ES2308551T3 (de)
HR (1) HRP20080429T3 (de)
IL (1) IL182423A0 (de)
MX (1) MX2007004464A (de)
NO (1) NO20071794L (de)
NZ (1) NZ554353A (de)
PL (1) PL1802625T3 (de)
PT (1) PT1802625E (de)
RU (1) RU2394826C2 (de)
SI (1) SI1802625T1 (de)
TW (1) TWI309652B (de)
WO (1) WO2006040036A1 (de)
ZA (1) ZA200702973B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
AU2006301292A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (de) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidin-derivate als jak1-inhibitoren
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
EP3353164B1 (de) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl-substituierte 1,4-benzodiazepine und ihre anwendung in der krebsbehandlung
CN106928040A (zh) * 2015-12-31 2017-07-07 上海医药工业研究院 Sglt2抑制剂中间体的制备方法
CA3046809A1 (en) * 2016-12-12 2018-06-21 The University Of Sydney Non-peptide oxytocin receptor agonists
RS66947B1 (sr) * 2016-12-13 2025-07-31 Transthera Sciences Nanjing Inc Jedinjenje inhibitora više kinaza, i njegova kristalna forma i upotreba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
EP4574823A1 (de) 2022-08-17 2025-06-25 Korea Research Institute of Chemical Technology Verbindungen zur hemmung oder zersetzung von cdk2 und/oder cdk9 und medizinische verwendungen davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681341A (en) 1970-12-23 1972-08-01 Hoffmann La Roche Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
ZA889116B (en) * 1987-12-18 1989-08-30 Hoffmann La Roche Tricyclic compounds
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof

Also Published As

Publication number Publication date
RU2007117770A (ru) 2008-11-20
HRP20080429T3 (en) 2008-09-30
WO2006040036A1 (en) 2006-04-20
KR100858262B1 (ko) 2008-09-11
JP2008515939A (ja) 2008-05-15
CN101899049A (zh) 2010-12-01
PL1802625T3 (pl) 2008-12-31
NZ554353A (en) 2010-01-29
US20060079511A1 (en) 2006-04-13
US7524840B2 (en) 2009-04-28
PT1802625E (pt) 2008-08-06
EP1802625B1 (de) 2008-06-18
BRPI0518152A (pt) 2008-11-04
RU2394826C2 (ru) 2010-07-20
AR051326A1 (es) 2007-01-03
EP1802625A1 (de) 2007-07-04
SI1802625T1 (sl) 2008-10-31
AU2005293818A1 (en) 2006-04-20
CN101039946A (zh) 2007-09-19
KR20070054243A (ko) 2007-05-28
CN101039946B (zh) 2010-12-08
CA2582985A1 (en) 2006-04-20
ES2308551T3 (es) 2008-12-01
IL182423A0 (en) 2007-07-24
TW200628469A (en) 2006-08-16
TWI309652B (en) 2009-05-11
DE602005007623D1 (de) 2008-07-31
ZA200702973B (en) 2009-09-30
DK1802625T3 (da) 2008-09-01
HK1108284A1 (en) 2008-05-02
NO20071794L (no) 2007-07-10
MX2007004464A (es) 2007-05-07

Similar Documents

Publication Publication Date Title
ATE398619T1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
IL258880A (en) Diarylhydantoin compounds
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
UA116188C2 (uk) Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
EP1667680A4 (de) Kombinationsverfahren zur behandlung von krebs
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
UA102250C2 (ru) Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
NO20055741L (no) Nye kjemiske forbindelser
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
ATE491948T1 (de) Gpr30-östrogenrezeptor bei mammakarzinomen
ATE520402T1 (de) Anti-egfr-antikörper und vegfr-inhibitoren umfassende kombinationen für die behandlung von krebs
NO20070043L (no) Fremgangsmåte for behandling av Fischer-Tropsch-hydrokarboner
ITTO20020994A1 (it) Materiali magnetici biocompatibili per il trattamento del cancro mediante ipertermia, e processi per la loro realizzazione.
ITFI20030150A1 (it) Metodo per la diagnosi del carcinoma della mammella.
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
DE502006009303D1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1802625

Country of ref document: EP